Evidence map›Paper›PMID 25255029›Full record

ArticleInternational journal of molecular sciences2014

Prediction of multi-target networks of neuroprotective compounds with entropy indices and synthesis, assay, and theoretical study of new asymmetric 1,2-rasagiline carbamates.

Francisco J Romero Durán, Nerea Alonso, Olga Caamaño, Xerardo García-Mera, Matilde Yañez, Francisco J Prado-Prado, Humberto González-Díaz

Abstract readComparative StudyValidation Study
In one paragraph

Article in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Machine Learning Study of Metabolic NetworksMolecular pharmaceutics · 2022
    Article
  5. Review
  6. Article
  7. Article
  8. Molecular science for drug development and biomedicine.International journal of molecular sciences · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francisco J Romero DuránDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain. fcojavier.romero@rai.usc.es.
Nerea AlonsoDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain. nerea.alonso@rai.usc.es.
Olga CaamañoDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain. molga.caamano@usc.es.
Xerardo García-MeraDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain. xerardo.garcía@usc.es.
Matilde YañezDepartment of Pharmacology, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain. matilde.yanez@usc.es.
Francisco J Prado-PradoDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela 15782, Spain. fprado@uqroo.mx.
Humberto González-DíazDepartment of Organic Chemistry II, Faculty of Science and Technology, University of the Basque Country UPV/EHU, Leioa 48940, Spain. humberto.gonzálezdíaz@ehu.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a multi-target complex network, the links (L(ij)) represent the interactions between the drug (d(i)) and the target (t(j)), characterized by different experimental measures (K(i), K(m), IC50, etc.) obtained in pharmacological assays under diverse boundary conditions (c(j)). In this work, we handle Shannon entropy measures for developing a model encompassing a multi-target network of neuroprotective/neurotoxic compounds reported in the CHEMBL database. The model predicts correctly >8300 experimental outcomes with Accuracy, Specificity, and Sensitivity above 80%-90% on training and external validation series. Indeed, the model can calculate different outcomes for >30 experimental measures in >400 different experimental protocolsin relation with >150 molecular and cellular targets on 11 different organisms (including human). Hereafter, we reported by the first time the synthesis, characterization, and experimental assays of a new series of chiral 1,2-rasagiline carbamate derivatives not reported in previous works. The experimental tests included: (1) assay in absence of neurotoxic agents; (2) in the presence of glutamate; and (3) in the presence of H2O2. Lastly, we used the new Assessing Links with Moving Averages (ALMA)-entropy model to predict possible outcomes for the new compounds in a high number of pharmacological tests not carried out experimentally.

Indexed as

EntropyAlgorithmsAnimalsCarbamatesCells, CulturedCell SurvivalCerebral CortexDatabases, PharmaceuticalDrug Evaluation, PreclinicalGlutamic AcidIndansModels, ChemicalMolecular StructureNeuroprotective AgentsQuantitative Structure-Activity RelationshipRatsCarbamatesGlutamic AcidIndansNeuroprotective Agentsrasagiline

Identifiers

PMID25255029
PMCPMC4200850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.